Cantor Fitzgerald Reiterates Overweight Rating on Prenetics with Price Target of $31 Following Strong IM8 Growth

Rhea-AI Summary

Prenetics (NASDAQ: PRE) received an Overweight reiteration from Cantor Fitzgerald with a revised 12‑month price target of $31 on Nov 11, 2025. Cantor highlighted IM8 performance: 3Q25 revenue $23.6M (≈568% YoY) and IM8 revenue $17.2M (≈76% sequential) with ~60% gross margins and a ~3.9‑month customer payback.

Cantor cites ~$120M total liquidity including ~387 BTC (~$41M), and forecasts FY2026 revenue ≈ $217M. The $31 target reflects model adjustments for a planned Europa divestment; Cantor still views PRE as undervalued at ~0.7× EV/2026E revenue versus ~1.1× peers.

Positive

• 3Q25 revenue of $23.6M (≈568% YoY)
• IM8 revenue $17.2M, +76% sequential
• Gross margins of ~60% for IM8
• Customer payback period of ~3.9 months
• Total liquidity of ~ $120M (including 387 BTC ≈ $41M)
• Cantor forecasts FY2026 revenue ≈ $217M

Negative

• Cantor reduced 12‑month price target from $32 to $31
• Planned divestment of Europa business required valuation model adjustments

Insights

Equity Analyst

Cantor's reiteration reflects strong IM8 unit economics, sizable liquidity and a bullish FY2026 revenue forecast, despite model tweaks tied to a Europa divestment.

IM8 is the operational driver: 3Q25 revenue reached $23.6 million with IM8 contributing $17.2 million, ~60% gross margins and a customer payback of ~3.9 months. Cantor cites an ~80%+ subscription rate and projects company revenue of roughly $217 million in FY2026, which underpins its continued Overweight view and the updated $31 12‑month target.

Key dependencies and risks are explicit: Cantor lowered its target slightly due solely to model adjustments for the planned Europa divestment, and the firm's stated liquidity position—~$120 million total, including ~387 BTC (~$41 million)—is central to near‑term financial flexibility. Monitor confirmation and timing of the Europa divestment, actual realization of forecasted international IM8 scale, and quarter‑over‑quarter margin trends for validation of the FY2026 revenue projection.

IM8’s Strong Unit Economics—60% Margins and 3.9-Month Payback—Central to Cantor’s Bullish Outlook

Cantor Notes PRE’s ~$120M Liquidity and 387 BTC Treasury as Strengthening the Company’s Financial Position

Cantor Forecasts $217 Million in FY2026 Revenue as IM8 Expands Internationally and Sharpens Strategic Focus

CHARLOTTE, N.C., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced that Cantor Fitzgerald has reiterated its Overweight rating on the Company in its latest equity research report dated November 11, 2025, while updating its 12-month price target to $31, compared to its prior target of $32. Cantor noted that this adjustment reflects valuation model updates related specifically to the Company’s planned divestment of its Europa business, with no change to its core investment thesis on Prenetics.

In its report, Cantor highlights the Company’s strong operating execution and IM8’s accelerating performance:

• 3Q25 revenue of $23.6 million, representing ~568% year-over-year growth
• IM8 revenue of $17.2 million, up ~76% sequentially with ~60% gross margins
• Customer payback period of ~3.9 months and 80%+ subscription rate
• ~387 BTC held as of November 10 (~$41 million), contributing to total liquidity of approximately $120 million
• Cantor forecasts FY2026 revenue of approximately $217 million, reflecting continued IM8 momentum and international scale-up
  

Cantor continues to view Prenetics as undervalued, noting PRE trades at just 0.7× EV/2026E revenue, compared to approximately 1.1× for consumer-health peers.

Cantor’s Price Target Evolution Throughout 2025

• September 16, 2025: Price target increased from $14 → $26 following strong 2Q25 performance
• October 28, 2025: Price target increased from $26 → $32 following $44 Million Equity Offering
• November 11, 2025: Price target updated to $31, driven solely by model adjustments tied to the upcoming Europa divestment, with Cantor reiterating its Overweight rating and long-term positive view on IM8 and Prenetics’ growth strategy
  

Management Commentary

Danny Yeung, CEO of Prenetics, commented:

“Cantor’s continued research coverage further underscores our emergence as a global leader in health and longevity. As IM8 scales across multiple international markets, the conviction from a respected institution like Cantor strengthens our position and widens investor understanding of the magnitude of the opportunity ahead.”

Cantor Fitzgerald's rating system

Overweight/OW: We expect the stock’s total return to exceed 15% over the next 12 months. For the purpose of calculating the percentage of subject companies within the Buy, Hold, and Sell categories for whom Cantor Fitzgerald has provided investment banking services within the previous 12 months, an Overweight rating equates to a Buy rating.

Neutral/N: We expect the stock’s total return to be between -10% and 15% over the next 12 months. For the purpose of calculating the percentage of subject companies within the Buy, Hold, and Sell categories for whom Cantor Fitzgerald has provided investment banking services within the previous 12 months, a Neutral rating equates to a Hold rating.

Underweight/UW: We expect the stock’s total return to fall below -10% over the next 12 months. For the purpose of calculating the percentage of subject companies within the Buy, Hold, and Sell categories for whom Cantor Fitzgerald has provided investment banking services within the previous 12 months, an Underweight rating equates to a Sell rating.

Important Note Regarding Analyst Reports

Please note that any opinions, estimates or forecasts regarding Prenetics performance made by research analysts, including Cantor, are theirs alone and do not represent opinions, forecasts or predictions of Prenetics or its management. Prenetics does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. 

About Prenetics
Prenetics (NASDAQ: PRE) is a leading health sciences company redefining the future of health and longevity through IM8 — its flagship consumer brand co-founded with David Beckham and championed by World No. 1 tennis player Aryna Sabalenka. IM8 has achieved the fastest growth trajectory in supplement industry history, reaching $100 million+ in ARR within 11 months of launch, outpacing even leading AI startups.

As the first consumer health company to establish a Bitcoin treasury, Prenetics continues to pioneer at the intersection of health innovation and digital assets - purchasing 1 Bitcoin per day, now totaling 390 BTC as of November 13, 2025.

About IM8
IM8 is the pinnacle of premium core nutrition, born from a collaboration between David Beckham as a co-founding partner, and an elite team of scientists spanning medical professionals, academia and space science. Combining cutting-edge science with nature’s most potent ingredients, IM8 delivers a holistic, science-backed approach to health, empowering you to live your most vibrant life. IM8’s flagship product, Daily Ultimate Essentials is an all-in-one powder supplement engineered to replace 16 different supplements in a delicious drink and is NSF Certified for Sport, non-GMO, vegan, free from common allergens, and contains no artificial flavors, colors or sweeteners. IM8 is a subsidiary of Prenetics (NASDAQ: PRE), a leading global health sciences company dedicated to advancing consumer health. To learn more about IM8, please visit www.IM8health.com.

Investor Relations Contact:
investors@prenetics.com
PRE@mzgroup.us

Angela Cheung
Investor Relations / Corporate Finance
angela.hm.cheung@prenetics.com

Forward-Looking Statements
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s goals, targets, projections, outlooks, beliefs, expectations, strategy, plans, objectives of management for future operations of the Company, and growth opportunities are forward-looking statements. Our guidance (including revenue ranges and breakdown timing) reflects management’s current estimates and assumptions as of the date of this release, is subject to significant risks and uncertainties, and is not a guarantee of future performance. Actual results may differ materially. In some cases, forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to,” “guidance,” “outlook,” “forecast,” or other similar expressions. Forward-looking statements are based upon estimates and forecasts and reflect the views, assumptions, expectations, and opinions of the Company, which involve inherent risks and uncertainties, and therefore they should not be relied upon as being necessarily indicative of future results. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to: future alpha-generating activities involving the Company’s Bitcoin holdings could expose it to additional risks; the Company’s purchase of Bitcoin subjects it to risks related to extreme volatility and speculative nature of Bitcoin; the Company may not be able to maintain and enhance its IM8 business and brand if it suffers negative publicity or fails to maintain a strong base of engaged customers and content creators, or otherwise fails to meet customers’ expectations; the Company’s ability to further develop and grow its business, including new products and services; its ability to execute on its new business strategy in genomics, precision oncology, and specifically, early detection for cancer; the results of case control studies and/or clinical trials; and its ability to identify and execute on M&A opportunities. In addition to the foregoing factors, you should also carefully consider the other risks and uncertainties described in the “Risk Factors” section of the Company’s most recent registration statement and the prospectus therein, and the other documents filed by the Company from time to time with the U.S. Securities and Exchange Commission. Unless otherwise specified, all information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

FAQ

What did Cantor Fitzgerald announce about Prenetics (PRE) on November 11, 2025?

Cantor reiterated an Overweight rating and set a 12‑month price target of $31, updating its model for an upcoming Europa divestment.

How large was Prenetics' 3Q25 revenue and IM8 contribution (PRE)?

3Q25 revenue was $23.6M, with IM8 contributing $17.2M.

What are IM8 unit economics cited by Cantor for PRE?

Cantor reported IM8 gross margins of ~60% and a customer payback period of ~3.9 months.

How much liquidity does Prenetics (PRE) hold according to Cantor?

Cantor cites approximately $120M total liquidity, including ~387 BTC (~$41M) as of Nov 10, 2025.

What revenue does Cantor forecast for Prenetics (PRE) in FY2026?

Cantor forecasts approximately $217 million in FY2026 revenue driven by IM8 international expansion.

How does Cantor value PRE versus consumer‑health peers?

Cantor notes PRE trades at about 0.7× EV/2026E revenue versus roughly 1.1× for consumer‑health peers.